Outcomes of maintenance therapy with lenalidomide or bortezomib in multiple myeloma in the setting of early autologous stem cell transplantation

Post-transplant maintenance is widely used in multiple myeloma (MM); however, there is a lack of data on real-world outcomes. We have analyzed 577 patients with newly diagnosed MM undergoing early auto-transplantation between 2010 and 2015. A total of 341, 132 and 104 patients received no, lenalidom...

Full description

Saved in:
Bibliographic Details
Published in:Leukemia 2018-03, Vol.32 (3), p.712-718
Main Authors: Chakraborty, R, Muchtar, E, Kumar, S K, Buadi, F K, Dingli, D, Dispenzieri, A, Hayman, S R, Hogan, W J, Kapoor, P, Lacy, M Q, Leung, N, Warsame, R, Kourelis, T, Gonsalves, W, Gertz, M A
Format: Article
Language:English
Subjects:
692/308/174
692/699/1541/1990/804
Autografts
Bortezomib
Cancer Research
Comparative analysis
Complications and side effects
Critical Care Medicine
Cytogenetics
Dosage and administration
Fluorescence
Fluorescence in situ hybridization
Health risk assessment
Hematology
Immunotherapy
Inhibitor drugs
Intensive
Internal Medicine
Lenalidomide
Maintenance
Medicine
Medicine & Public Health
Multiple myeloma
Oncology
original-article
Patient outcomes
Patients
Risk
Risk groups
Stem cell transplantation
Subgroups
Targeted cancer therapy
Toxicity
Transplantation
Transplants & implants
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Post-transplant maintenance is widely used in multiple myeloma (MM); however, there is a lack of data on real-world outcomes. We have analyzed 577 patients with newly diagnosed MM undergoing early auto-transplantation between 2010 and 2015. A total of 341, 132 and 104 patients received no, lenalidomide (Len) or bortezomib (Bort) maintenance, respectively. Patients receiving Len or Bort maintenance had a higher incidence of high-risk cytogenetics by fluorescence in situ hybridization (31% (Len) vs 58% (Bort) vs 8% (No); P
ISSN:0887-6924
1476-5551
DOI:10.1038/leu.2017.256